WO2014076221A1 - Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections - Google Patents

Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections Download PDF

Info

Publication number
WO2014076221A1
WO2014076221A1 PCT/EP2013/073901 EP2013073901W WO2014076221A1 WO 2014076221 A1 WO2014076221 A1 WO 2014076221A1 EP 2013073901 W EP2013073901 W EP 2013073901W WO 2014076221 A1 WO2014076221 A1 WO 2014076221A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
formula
amino
mmol
Prior art date
Application number
PCT/EP2013/073901
Other languages
French (fr)
Inventor
Stefaan Julien Last
David Craig Mc Gowan
Werner Embrechts
Serge Maria Aloysius Pieters
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Original Assignee
Janssen R&D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47189782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014076221(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020157010310A priority Critical patent/KR102253773B1/en
Priority to CN201380059827.3A priority patent/CN105051018B/en
Priority to EP13789821.9A priority patent/EP2925729B1/en
Priority to CA2886635A priority patent/CA2886635C/en
Priority to US14/443,305 priority patent/US9663474B2/en
Priority to UAA201505893A priority patent/UA118341C2/en
Priority to BR112015011036-3A priority patent/BR112015011036B1/en
Priority to DK13789821.9T priority patent/DK2925729T3/en
Priority to SG11201503042QA priority patent/SG11201503042QA/en
Application filed by Janssen R&D Ireland filed Critical Janssen R&D Ireland
Priority to JP2015542270A priority patent/JP6297055B2/en
Priority to EA201590931A priority patent/EA035431B1/en
Priority to MX2015006197A priority patent/MX361585B/en
Priority to NZ70622613A priority patent/NZ706226A/en
Priority to PL13789821T priority patent/PL2925729T3/en
Priority to ES13789821.9T priority patent/ES2655843T3/en
Priority to AU2013346793A priority patent/AU2013346793B2/en
Publication of WO2014076221A1 publication Critical patent/WO2014076221A1/en
Priority to IL237864A priority patent/IL237864A/en
Priority to PH12015500983A priority patent/PH12015500983A1/en
Priority to US15/591,473 priority patent/US10253003B2/en
Priority to US16/377,752 priority patent/US10723707B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to heterocyclic substituted 2-amino-quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
  • the present invention relates to the use of heterocyclic substituted 2-amino- quinazoline derivatives in the treatment of viral infections, immune or inflammatory disorders, whereby the modulation, or agonism, of toll-like- receptors (TLRs) is involved.
  • TLRs toll-like- receptors
  • Toll-Like Receptors are primary transmembrane proteins characterized by an extracellular leucine rich domain and a cytoplasmic extension that contains a conserved region.
  • the innate immune system can recognize pathogen-associated molecular patterns via these TLRs expressed on the cell surface of certain types of immune cells. Recognition of foreign pathogens activates the production of cytokines and upregulation of co- stimulatory molecules on phagocytes. This leads to the modulation of T cell behaviour.
  • TLR1 to TLR13 TLRs
  • TLR1 to TLR13 TLRs
  • equivalent forms of many of these have been found in other mammalian species.
  • equivalents of certain TLR found in humans are not present in all mammals.
  • a gene coding for a protein analogous to TLR10 in humans is present in mice, but appears to have been damaged at some point in the past by a retrovirus.
  • mice express TLRs 1 1 , 12, and 13, none of which are represented in humans.
  • Other mammals may express TLRs which are not found in humans.
  • Other non-mammalian species may have TLRs distinct from mammals, as demonstrated by TLR14, which is found in the Takifugu pufferfish. This may complicate the process of using experimental animals as models of human innate immunity.
  • Ri is any of the following structures
  • R 2 is hydrogen, -O-(Ci -3 )-alkyl, halogen, (Ci -3 )-alkyl, -O-(Ci -3 )-alkyl-O-(Ci -3 )- alkyl or CH 2 OH;
  • R 4 is hydrogen or fluorine
  • Rs is (Ci -3 )-alkyl, (Ci -3 )-fluoro-alkyl or CH 2 OH;
  • R 6 is NH 2 , NH(CH 3 ) or N(CH 3 ) 2 , (hetero)-anilines optionally substituted with one or more R 3 , R9, R10 R11 or Ri 2 or (hetero)-benzylamines optionally substituted with one or more R 3 , R9, R10 R11 or Ri 2 ,
  • R 8 , R9, R10, R11 and Ri 2 which are the same or different, are each independently selected from hydrogen, (Ci -3 )-alkyl, -O-(Ci -3 )-alkyl or halogen and
  • Ri 3 is hydrogen, (Ci -3 )-alkyl or (Ci -3 )-fluoro-alkyl.
  • Preferred compounds according to the invention are compounds with the numbers 12 and 29 as depicted in Table II.
  • the compounds of formula (I) and their pharmaceutically acceptable salts, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof have activity as pharmaceuticals, in particular as modulators of Toll-Like Receptors (especially TLR7 and/or TLR8 activity).
  • the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, stereo-isomeric form, solvate or polymorph thereof together with one or more pharmaceutically acceptable excipients, diluents or carriers.
  • a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, stereo-isomeric form or polymorph thereof according to the current invention, or a pharmaceutical composition comprising said compound of formula(l) or a pharmaceutically acceptable salt, solvate, tautomer, stereo- isomeric form or polymorph thereof can be used as a medicament.
  • a compound of formula (I) or its pharmaceutically acceptable salt, solvate, tautomer, stereo-isomeric form or polymorph thereof, or said pharmaceutical composition comprising said compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, stereo-isomeric form or polymorph thereof can be used accordingly in the treatment of a disorder in which the modulation of TLR7 and /or TLR8 is involved.
  • (Ci-3)-alkyl refers to a straight-chain, branched-chain or cyclic saturated aliphatic hydrocarbon containing the specified number of carbon atoms.
  • (Ci-3)-fluoro-alkyl refers to a straight-chain, branched-chain or cyclic saturated aliphatic hydrocarbon containing the specified number of carbon atoms where one or more hydrogen atoms was replaced by a fluorine atom.
  • halogen refers to fluorine, chlorine, bromine or iodine, preferably to fluorine and chlorine.
  • aniline refers a compound with the formula C6H 5 NR13- consisting of a phenyl group attached to an amino group; with “(hetero)-aniline” is meant that in the aromatic ring 1 -3 nitrogen atoms, preferably 1 nitrogen atom, are present.
  • benzylamine means a compound of the formula C6H 5 CH2NR13- consisting of a benzyl group, C6H 5 CH 2 , attached to an amine functional group; with “(hetero)-benzylamine” is meant that in the aromatic ring 1 -3 nitrogen atoms, preferably 1 nitrogen atom, are present.
  • any chemical formula with bonds shown only as solid lines and not as solid wedged or hashed wedged bonds, or otherwise indicated as having a particular configuration (e.g. R, S) around one or more atoms contemplates each possible stereoisomer, or mixture of two or more stereoisomers.
  • stereoisomers stereoisomers
  • stereoisomeric forms or “stereochemically isomeric forms” hereinbefore or hereinafter are used interchangeably.
  • the invention includes all stereoisomers of the compounds of the invention either as a pure stereoisomer or as a mixture of two or more stereoisomers.
  • Enantiomers are stereoisomers that are non-superimposable mirror images of each other.
  • a 1 :1 mixture of a pair of enantiomers is a racemate or racemic mixture.
  • Diastereomers are stereoisomers that are not enantiomers, i.e. they are not related as mirror images. If a compound contains a double bond, the substituents may be in the E or the Z configuration. If a compound contains an at least disubstituted non-aromatic cyclic group, the substituents may be in the cis or trans configuration.
  • the invention includes enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, whenever chemically possible.
  • the meaning of all those terms, i.e. enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof are known to the skilled person.
  • the absolute configuration is specified according to the Cahn-lngold-Prelog system.
  • the configuration at an asymmetric atom is specified by either R or S.
  • Resolved stereoisomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
  • resolved enantiomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light.
  • Pharmaceutically acceptable salts of the compounds of formula (I) include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Suitable base salts are formed from bases which form non-toxic salts.
  • the compounds of the invention may also exist in unsolvated and solvated forms.
  • solvate is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
  • polymorph refers to the ability of the compound of the invention to exist in more than one form or crystal structure.
  • the compounds of the present invention may be administered as crystalline or amorphous products. They may be obtained for example as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs. Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients.
  • excipient is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient depends largely on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
  • compositions of the present invention may be formulated into various pharmaceutical forms for administration purposes.
  • compositions there may be cited all compositions usually employed for systemically administering drugs.
  • an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • These pharmaceutical compositions are desirably in unitary dosage form suitable, for example, for oral, rectal, or percutaneous administration.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions, and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. Also included are solid form preparations that can be converted, shortly before use, to liquid forms.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions.
  • These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment.
  • the compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way.
  • the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder. It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage.
  • Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
  • an effective daily amount would be from 0.01 mg/kg to 50 mg/kg body weight, more preferably from 0.1 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.
  • the exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective amount ranges mentioned above are therefore only guidelines and are not intended to limit the scope or use of the invention to any extent.
  • Table I Compounds of formula (III). The following internnediates were prepared according to the method to prepare 111-1.
  • 2-amino-8-fluoro-5-methoxy-quinazolin-4-ol 150 mg, 0.72 mmol was dispensed in DMF (10 ml_), DBU (0.536 ml_, 3.59 mmol), was added and then BOP reagent (396 mg, 0.90 mmol) was added. The reaction mixture was stirred and when it was homogeneous (5-methyl-3-isoxazolyl)methylamine (0.1 15 ml_, 1 .08 mmol) was added. The reaction mixture was stirred 16 hours.
  • Table II Compounds of formula (I). The following compounds were nthesized according to one of the methods described above.
  • the Supercritical Fluid Chromatography (SFC) separation was performed with supercritical CO 2 and a modifier as specified in the table using a column as specified in the table.
  • Table III Compounds of formula (I). The following compounds were isolated SFC separation.
  • HPLC High Performance Liquid Chromatography
  • MS Mass Spectrometer
  • SQL Single Quadrupole Detector
  • MSD Mass Selective Detector
  • RT room temperature
  • BEH bridged ethylsiloxane/silica hybrid
  • DAD Diode Array Detector
  • HSS High Strength silica
  • Table IV LCMS Method codes (Flow expressed in mL/min; column temperature (T) in °C; Run time in minutes).
  • Table V Compounds of formula (I). The following compounds characterized accordin to one of the methods described above.
  • TLR7 and TLR8 activity The ability of compounds to activate human TLR7 and/or TLR8 was assessed in a cellular reporter assay using HEK293 cells transiently transfected with a TLR7 or TLR8 expression vector and N FKB-IUC reporter construct.
  • HEK293 cells were grown in culture medium (DMEM supplemented with 10% FCS and 2 mM Glutamine).
  • DMEM fetal bovine serum
  • a transfection reagent for transfection of cells in 15 cm dishes, cells were detached with Trypsin-EDTA, transfected with a mix of CMV-TLR7 or TLR8 plasmid (1700 ng), N FKB-IUC plasmid (850 ng) and a transfection reagent and incubated for 48 h at 37°C in a humidified 5% CO2 atmosphere. Transfected cells were then washed in PBS, detached with Trypsin-EDTA and resuspended in medium to a density of 1 .25 x 10 5 cells/mL.
  • Compound toxicity was determined in parallel using a similar dilution series of compound with 40 ⁇ per well of cells transfected with the CMV-TLR7 construct alone (1 .25 x 10 5 cells/mL), in 384-well plates. Cell viability was measured after 6 hours incubation at 37°C, 5% CO2 by adding 15 ⁇ of ATP lite (Perkin Elmer) per well and reading on a ViewLux ultraHTS microplate imager (Perkin Elmer). Data was reported as CC 5 0.
  • the potential of compounds to induce IFN-I was also evaluated by measuring the activation of interferon-stimulated responsive elements (ISRE) by conditioned media from PBMC.
  • ISRE interferon-stimulated responsive elements
  • the ISRE element of sequence GAAACTGAAACT is highly responsive to the STAT1 -STAT2-IRF9 transcription factor, activated upon binding of IFN-I to their receptor IFNAR (Clontech, PT3372-5W).
  • the plasmid pISRE-Luc from Clontech contains 5 copies of this ISRE element, followed by the firefly luciferase ORF.
  • a HEK293 cell line stably transfected with pISRE-Luc (HEK-ISREluc) was established to profile the conditioned PBMC cell culture media.
  • PBMCs were prepared from buffy coats of at least two donors using a standard Ficoll centrifugation protocol. Isolated PBMCs were resuspended in RPMI medium supplemented with 10% human AB serum and 2 x 10 5 cells/well were dispensed into 384-well plates containing compounds (70 ⁇ _ total volume). After overnight incubation, 10 ⁇ _ of supernatant was transferred to 384-well plates containing 5 x 10 3 HEK-ISREluc cells/well in 30 ⁇ _ (plated the day before).
  • NA not available. All compounds showed no toxicity up to the highest tested concentration. All compounds showed no activity (LEC >25 ⁇ ) in the HEK 293 NF-kB counterscreen assay described above.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to heterocyclic substituted 2-amino-quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

Description

HETEROCYCLIC SUBSTITUTED 2-AMINO-QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
This invention relates to heterocyclic substituted 2-amino-quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.
The present invention relates to the use of heterocyclic substituted 2-amino- quinazoline derivatives in the treatment of viral infections, immune or inflammatory disorders, whereby the modulation, or agonism, of toll-like- receptors (TLRs) is involved. Toll-Like Receptors are primary transmembrane proteins characterized by an extracellular leucine rich domain and a cytoplasmic extension that contains a conserved region. The innate immune system can recognize pathogen-associated molecular patterns via these TLRs expressed on the cell surface of certain types of immune cells. Recognition of foreign pathogens activates the production of cytokines and upregulation of co- stimulatory molecules on phagocytes. This leads to the modulation of T cell behaviour.
It has been estimated that most mammalian species have between ten and fifteen types of Toll-like receptors. Thirteen TLRs (named TLR1 to TLR13) have been identified in humans and mice together, and equivalent forms of many of these have been found in other mammalian species. However, equivalents of certain TLR found in humans are not present in all mammals. For example, a gene coding for a protein analogous to TLR10 in humans is present in mice, but appears to have been damaged at some point in the past by a retrovirus. On the other hand, mice express TLRs 1 1 , 12, and 13, none of which are represented in humans. Other mammals may express TLRs which are not found in humans. Other non-mammalian species may have TLRs distinct from mammals, as demonstrated by TLR14, which is found in the Takifugu pufferfish. This may complicate the process of using experimental animals as models of human innate immunity.
For reviews on TLRs see the following journal articles. Hoffmann, J. A., Nature, 426, p33-38, 2003; Akira, S., Takeda, K., and Kaisho, T., Annual Rev. Immunology, 21 , p335-376, 2003; Ulevitch, R. J., Nature Reviews: Immunology, 4, p512-520, 2004. Compounds indicating activity on Toll-Like receptors have been previously described such as purine derivatives in WO 2006/1 17670, adenine derivatives in WO 98/01448 and WO 99/28321 , and pyrimidines in WO 2009/067081 .
However, there exists a strong need for novel Toll-Like receptor modulators having preferred selectivity, higher potency, higher metabolic stability, and an improved safety profile compared to the compounds of the prior art.
In accordance with the present invention a compound of formula (I) is provided
Figure imgf000003_0001
or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof, wherein
Ri is any of the following structures
Figure imgf000003_0002
Figure imgf000004_0001
R2 is hydrogen, -O-(Ci-3)-alkyl, halogen, (Ci-3)-alkyl, -O-(Ci-3)-alkyl-O-(Ci-3)- alkyl or CH2OH; R3 is hydrogen, -O-(Ci-3)-alkyl, halogen, (Ci-3)-alkyl or -C(=O)-R7 wherein R7 is -O-(Ci-3)-alkyl, NH2, NH(CH3), N(CH3)2, N(CH3)(Ci-3)-alkyl, N((Ci-3)-alkyl)2 or pyrolidine;
R4 is hydrogen or fluorine;
Rs is (Ci-3)-alkyl, (Ci-3)-fluoro-alkyl or CH2OH;
R6 is NH2, NH(CH3) or N(CH3)2, (hetero)-anilines optionally substituted with one or more R3, R9, R10 R11 or Ri2 or (hetero)-benzylamines optionally substituted with one or more R3, R9, R10 R11 or Ri2,
R8, R9, R10, R11 and Ri2 which are the same or different, are each independently selected from hydrogen, (Ci-3)-alkyl, -O-(Ci-3)-alkyl or halogen and
Ri3 is hydrogen, (Ci-3)-alkyl or (Ci-3)-fluoro-alkyl.
Preferred compounds according to the invention are compounds with the numbers 12 and 29 as depicted in Table II.
The compounds of formula (I) and their pharmaceutically acceptable salts, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof have activity as pharmaceuticals, in particular as modulators of Toll-Like Receptors (especially TLR7 and/or TLR8 activity). In a further aspect the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, stereo-isomeric form, solvate or polymorph thereof together with one or more pharmaceutically acceptable excipients, diluents or carriers. Furthermore a compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, stereo-isomeric form or polymorph thereof according to the current invention, or a pharmaceutical composition comprising said compound of formula(l) or a pharmaceutically acceptable salt, solvate, tautomer, stereo- isomeric form or polymorph thereof can be used as a medicament. Another aspect of the invention is that a compound of formula (I) or its pharmaceutically acceptable salt, solvate, tautomer, stereo-isomeric form or polymorph thereof, or said pharmaceutical composition comprising said compound of formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, stereo-isomeric form or polymorph thereof can be used accordingly in the treatment of a disorder in which the modulation of TLR7 and /or TLR8 is involved.
The term "(Ci-3)-alkyl" refers to a straight-chain, branched-chain or cyclic saturated aliphatic hydrocarbon containing the specified number of carbon atoms. The term "(Ci-3)-fluoro-alkyl" refers to a straight-chain, branched-chain or cyclic saturated aliphatic hydrocarbon containing the specified number of carbon atoms where one or more hydrogen atoms was replaced by a fluorine atom.
The term "halogen" refers to fluorine, chlorine, bromine or iodine, preferably to fluorine and chlorine. The term "aniline" refers a compound with the formula C6H5NR13- consisting of a phenyl group attached to an amino group; with "(hetero)-aniline" is meant that in the aromatic ring 1 -3 nitrogen atoms, preferably 1 nitrogen atom, are present.
The term "benzylamine" means a compound of the formula C6H5CH2NR13- consisting of a benzyl group, C6H5CH2, attached to an amine functional group; with "(hetero)-benzylamine" is meant that in the aromatic ring 1 -3 nitrogen atoms, preferably 1 nitrogen atom, are present. As used herein, any chemical formula with bonds shown only as solid lines and not as solid wedged or hashed wedged bonds, or otherwise indicated as having a particular configuration (e.g. R, S) around one or more atoms, contemplates each possible stereoisomer, or mixture of two or more stereoisomers. The terms "stereoisomers", "stereoisomeric forms" or "stereochemically isomeric forms" hereinbefore or hereinafter are used interchangeably.
The invention includes all stereoisomers of the compounds of the invention either as a pure stereoisomer or as a mixture of two or more stereoisomers. Enantiomers are stereoisomers that are non-superimposable mirror images of each other. A 1 :1 mixture of a pair of enantiomers is a racemate or racemic mixture.
Diastereomers (or diastereoisomers) are stereoisomers that are not enantiomers, i.e. they are not related as mirror images. If a compound contains a double bond, the substituents may be in the E or the Z configuration. If a compound contains an at least disubstituted non-aromatic cyclic group, the substituents may be in the cis or trans configuration.
Therefore, the invention includes enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof, whenever chemically possible. The meaning of all those terms, i.e. enantiomers, diastereomers, racemates, E isomers, Z isomers, cis isomers, trans isomers and mixtures thereof are known to the skilled person.
The absolute configuration is specified according to the Cahn-lngold-Prelog system. The configuration at an asymmetric atom is specified by either R or S. Resolved stereoisomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light. For instance, resolved enantiomers whose absolute configuration is not known can be designated by (+) or (-) depending on the direction in which they rotate plane polarized light. When a specific stereoisomer is identified, this means that said stereoisomer is substantially free, i.e. associated with less than 50%, preferably less than 20%, more preferably less than 10%, even more preferably less than 5%, in particular less than 2% and most preferably less than 1 %, of the other stereoisomers. Thus, when a compound of Formula (I) is for instance specified as (R), this means that the compound is substantially free of the (S) isomer; when a compound of Formula (I) is for instance specified as E, this means that the compound is substantially free of the Z isomer; when a compound of Formula (I) is for instance specified as cis, this means that the compound is substantially free of the trans isomer.
Pharmaceutically acceptable salts of the compounds of formula (I) include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids which form non-toxic salts. Suitable base salts are formed from bases which form non-toxic salts.
The compounds of the invention may also exist in unsolvated and solvated forms. The term "solvate" is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term "polymorph" refers to the ability of the compound of the invention to exist in more than one form or crystal structure.
The compounds of the present invention may be administered as crystalline or amorphous products. They may be obtained for example as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. They may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs. Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term "excipient" is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient depends largely on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
The compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, for example, for oral, rectal, or percutaneous administration. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions, and solutions; or solid carriers such as starches, sugars, kaolin, diluents, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are obviously employed. Also included are solid form preparations that can be converted, shortly before use, to liquid forms. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. The compounds of the present invention may also be administered via inhalation or insufflation by means of methods and formulations employed in the art for administration via this way. Thus, in general the compounds of the present invention may be administered to the lungs in the form of a solution, a suspension or a dry powder. It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, suppositories, injectable solutions or suspensions and the like, and segregated multiples thereof.
Those of skill in the treatment of infectious diseases will be able to determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective daily amount would be from 0.01 mg/kg to 50 mg/kg body weight, more preferably from 0.1 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 1 to 1000 mg, and in particular 5 to 200 mg of active ingredient per unit dosage form.
The exact dosage and frequency of administration depends on the particular compound of formula (I) used, the particular condition being treated, the severity of the condition being treated, the age, weight and general physical condition of the particular patient as well as other medication the individual may be taking, as is well known to those skilled in the art. Furthermore, it is evident that the effective amount may be lowered or increased depending on the response of the treated subject and/or depending on the evaluation of the physician prescribing the compounds of the instant invention. The effective amount ranges mentioned above are therefore only guidelines and are not intended to limit the scope or use of the invention to any extent.
Preparation of compounds of formula (I)
Compounds of formula (I) are prepared according to scheme 1. Substituted anthranilic esters or acids (II) were heated under acidic conditions in the presence of excess cyanamide, using an alcoholic solvent (e.g. ethanol) or diglyme according to the method described in the literature (O'Hara et. al. JOC (1991 ) 56, p776). Subsequent amine substitution of the 2-amino-4- hydroxyquinazolines (III) can proceed via a coupling agent such as BOP or PyBOP in the presence of DBU and the amine in a polar aprotic solvent (e.g. DMF).
Scheme 1 :
Figure imgf000009_0001
Experimental Section. General procedure of making a substituted 2-amino-4-hydroxyquinazoline
Figure imgf000010_0001
1 00°C
pressure vessel 111-1
Into a 500 mL pressure vessel equipped with a magnetic stir bar was placed 2- amino-6-methoxybenzoic acid (25 g, 149.6 mmol), ethanol (200 mL), cyanamide (9.43 g, 224 mmol), and concentrated HCI (6 mL). The mixture was allowed to stir at 100°C for 16h. The reaction mixture was allowed to cool to room temperature and the solids were isolated via filtration and washed with ethanol and DIPE. The crude product was dried under vacuum at 50°C to obtain an off white solid.
LC-MS m/z = 192(M+H)
1H NMR (400 MHz, DMSO-c/6) δ ppm 3.88 (s, 3 H), 6.96 (dd, J=8.2, 3.1 Hz, 2 H), 7.69 (t, J=8.3 Hz, 1 H), 8.28 (br. s., 2 H), 12.67 (br. s., 1 H)
Table I: Compounds of formula (III). The following internnediates were prepared according to the method to prepare 111-1.
Figure imgf000011_0001
Figure imgf000012_0001
General procedure of making compound IV
Compound III (1 .5 mmol) and DBU (3.75mmol) were dissolved in 5 ml_ DMF in a 30 ml_ glass vial. After 5 minutes BOP (1 .5 mmol) was added. The reaction mixture was stirred for 5 minutes and then the amine (2.25 mmol) was added. The reaction mixture was stirred overnight. The crude reaction mixture was purified by prep. HPLC on (RP Vydac Denali C18 - 10μηη, 250g, 5cm). Mobile phase (0.25% NH HCO3 solution in water, MeOH), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain the product as a solid.
General procedure to make compounds 22, 23, 24, 26, 27 and 28
Compound 8 of formula (I) (see table II) (2.1 g, 6.5mmol) was dispensed in THF (50 ml_), LiOH (409 mg, 9.74 mmol) was added followed by MeOH (5 ml_). The reaction mixture was stirred overnight at room temperature. The solvents were evaporated until only water remained. 10 ml_ 1 M HCI was added and the compound was extracted with 2-methyltetrahydrofuran (2 X 25 ml_). The combined organic layers were dried on MgSO4 and the solvents were removed under reduced pressure to obtain 2-amino-4-[1 -(2- pyridyl)ethylamino]quinazoline-7-carboxylic acid as a white solid. 2-amino-4-[1 -(2-pyridyl)ethylamino]quinazoline-7-carboxylic acid (200 mg, 0.65 mmol) and PyBOP (421 mg, 0.81 mmol) were dissolved in DMF(5 ml_) in a 30 ml_ glass vial. After 5 minutes Hunig's base (0.557 ml_, 3.23 mmol) was added. The reaction mixture was stirred for 5 minutes and then the amine was added. The reaction mixture was stirred overnight. The crude reaction mixture was purified by preparative. HPLC on (RP Vydac Denali C18 - 10μηη, 250g, 5cm). Mobile phase (0.25% NH HCO3 solution in water, MeOH), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain the product as a solid. Procedure to make compound 29
Compound 12 of formula (I) (see table II) (1500 mg, 4.78 mmol) and pyridine hydrochloride (3.32 g, 28.7 mmol) were dissolved in pyridine (20ml_) and heated to 120°C for 16h. Pyridine was removed under reduced pressure. The residual fraction was quenched with a NaHCO3 (sat.,aq.) solution. The precipitate was filtered off, washed with water and dried under vacuum at 50°C to afford a brown solid which was purified by preparative HPLC (Stationary phase: RP Vydac Denali C18 - 10μηη, 200g, 5cm), Mobile phase: 0.25% NH HCO3 solution in water, CH3CN), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain 2-amino-4-[(5- methylisoxazol-3-yl)methylamino]quinazolin-5-ol (100 mg) as a solid.
2-amino-4-[(5-methylisoxazol-3-yl)methylamino]quinazolin-5-ol (40 mg, 0.15 mmol) and CS2CO3 (144 mg, 0.44 mmol) were dissolved in DMF (7.5 mL) and stirred at room temperature for 30 minutes. 2-bromoethyl methyl ether (0.018 mL, 0.18 mmol) was added and the entire mixture was stirred for 16 hours at room temperature. The solvent was removed under reduced pressure and the crude residue was neutralized with 1 M HCI and purified by preparative HPLC on (RP Vydac Denali C18 - 10μηη, 250g, 5cm). Mobile phase (0.25% NH HCO3 solution in water, MeOH), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain compound 29 as a solid.
Procedure to make compound 30
A 75-mL stainless steel autoclave was charged under N2 atmosphere with 2- amino-5-bromo-quinazolin-4-ol (3 g, 12.5 mmol), Pd(OAc)2 (56 mg, 0.25 mmol), 1 ,3 bis(diphenylphosphino)propane (206 mg, 0.5 mmol), potassium acetate (2.45 g, 25 mmol), methanol (25 mL) and THF (30 mL). The autoclave was closed and pressurized to 50 bar CO gas and the reaction was carried out for 16 hours at 100°C. The formed precipitate was removed by filtration yielding methyl 2-amino-4-hydroxy-quinazoline-5-carboxylate (2.35 g).
Methyl 2-amino-4-hydroxy-quinazoline-5-carboxylate (2.35 g) in THF (10 ml_) was cooled to 0°C. Then LiAIH was added. The mixture was allowed to reach room temperature and stirred for 16 hours. EtOAc (5 ml_) was added drop wise at 0°C, then 3g Na2SO4.10H2O was added and the entire mixture was stirred for 30 minutes. The precipitate was filtered off, and the filtrate was dried with MgSO4, filtered and evaporated to dryness to obtain 2-amino-5- (hydroxymethyl)quinazolin-4-ol (750mg) as a yellow solid.
2-amino-5-(hydroxymethyl)quinazolin-4-ol (300 mg, 1 ,57 mmol) was suspended in THF (20 ml_) with DBU (0.586 ml_, 3.92 mmol), after 5 minutes BOP (833 mg, 1 .88 mmol) was added. After 15 minutes (5-methyl-3- isoxazolyl)methylamine (0.320 ml_, 3.14 mmol) was added. The mixture was stirred for 16 hours at room temperature. The solvent was removed under reduced pressure and the crude product was purified by preparative HPLC on (RP Vydac Denali C18 - 10μηη, 250g, 5cm). Mobile phase (0.25% NH4HCO3 solution in water, MeOH), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain compound 30 as a solid (1 19 mg).
Procedure to make compound 31
A freshly prepared NaOMe solution (1 .25 ml_, 6.25 mmol) was added under N2 atmosphere to a mixture of 2-amino-5-bromo-8-fluoro-quinazolin-4-ol (500 mg, 1 .94 mmol), copper (I) bromide (39 mg, 0.27 mmol), EtOAc (0.076 ml_, 0.78 mmol) in MeOH (5 ml_). The mixture was heated up in a pressure vessel to reflux for 16 hours. The solvent was removed under reduced pressure. The residue was purified by preparative HPLC (Stationary phase: RP Vydac Denali C18 - 10 pm, 200 g, 5 cm), Mobile phase: 0.25% NH4HCO3 solution in water, MeOH), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain 2-amino-8-fluoro-5-methoxy-quinazolin-4-ol (150 mg) as a solid.
2-amino-8-fluoro-5-methoxy-quinazolin-4-ol (150 mg, 0.72 mmol) was dispensed in DMF (10 ml_), DBU (0.536 ml_, 3.59 mmol), was added and then BOP reagent (396 mg, 0.90 mmol) was added. The reaction mixture was stirred and when it was homogeneous (5-methyl-3-isoxazolyl)methylamine (0.1 15 ml_, 1 .08 mmol) was added. The reaction mixture was stirred 16 hours. The reaction was concentrated under reduced pressure and the residue was purified by preparative HPLC (Stationary phase: RP Vydac Denali C18 - 10 μιτι, 200 g, 5 cm), Mobile phase: 0.25% NH4HCO3 solution in water, MeOH), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain compound 31 as a solid (64 mg).
Procedure to make compound 32
Compound 31 (52.5 mg, 0.173 mmol) and pyridine hydrochloride (0.12 g, 1 .039 mmol) in 1 ml_ pyridine was heated to 120°C for 16 hours. The volatiles were removed under reduced pressure. The residue was quenched with a NaHCO3 (sat., aq.) solution. The precipitate was filtered off, washed with water and dried under vacuum at 50°C to afford 2-amino-8-fluoro-4-[(5-methylisoxazol-3- yl)methylamino]quinazolin-5-ol (10 mg) as a brown solid.
2-amino-8-fluoro-4-[(5-methylisoxazol-3-yl)methylamino]quinazolin-5-ol (10 mg, 0.035 mmol) and Cs2CO3 (33.8 mg, 0.104 mmol) in DMF (5 ml_) was stirred at room temperature for 30 minutes. 2-chloroethyl methyl ether (4.1 mg, 0.043 mmol) was added and the entire mixture was stirred for 16 hours at room temperature. The solvent was removed under reduced pressure. The residue was dissolved in MeOH and the precipitate (salts) were removed by filtration. The filtrate was concentrated under reduced pressure and the crude residue was purified by preparative HPLC on (Stationary phase: RP SunFire Prep C18 OBD-10 μηη, 30 x 150 mm), Mobile phase: 0.25% NH4HCO3 solution in water, CH3CN), the desired fractions were collected, evaporated, dissolved in MeOH and evaporated again to obtain compound 32 as a solid (2 mg).
Table II: Compounds of formula (I). The following compounds were nthesized according to one of the methods described above.
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000019_0001
Figure imgf000020_0001
Figure imgf000021_0001
(m,
(m, - 1 H)
J=7.26 H) (t, 1.32 1 H) 9.39
(m, (d, 8.49
Figure imgf000022_0001
SFC purification methods.
General procedure
The Supercritical Fluid Chromatography (SFC) separation was performed with supercritical CO2 and a modifier as specified in the table using a column as specified in the table.
Table III: Compounds of formula (I). The following compounds were isolated SFC separation.
Figure imgf000023_0001
For all compounds the first eluting compound was assigned as *R.
*R means an enantiomeric pure configuration of which the absolute stereochemistry is unknown. Analytical Methods. General procedure
The High Performance Liquid Chromatography (HPLC) measurement was performed using a LC pump, a diode-array (DAD) or a UV detector and a column as specified in the respective methods. If necessary, additional detectors were included (see table of methods below).
Flow from the column was brought to the Mass Spectrometer (MS) which was configured with an atmospheric pressure ion source. It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time...) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software.
Compounds are described by their experimental retention times (Rt) and ions. If not specified differently in the table of data, the reported molecular ion corresponds to the [M+H]+ (protonated molecule) and/or [M-H]" (deprotonated molecule). In case the compound was not directly ionizable the type of adduct is specified (i.e. [M+NH4]+, [M+HCOO]", etc .). For molecules with multiple isotopic patterns (Br, CI..), the reported value is the one obtained for the lowest isotope mass. All results were obtained with experimental uncertainties that are commonly associated with the method used.
Hereinafter, "SQD" means Single Quadrupole Detector, "MSD" Mass Selective Detector, "RT" room temperature, "BEH" bridged ethylsiloxane/silica hybrid, "DAD" Diode Array Detector, "HSS" High Strength silica.
Table IV: LCMS Method codes (Flow expressed in mL/min; column temperature (T) in °C; Run time in minutes).
Figure imgf000025_0002
Table V: Compounds of formula (I). The following compounds characterized accordin to one of the methods described above.
Figure imgf000025_0001
Figure imgf000026_0001
Biological Activity of compounds of formula (I)
Description of Biological Assays
Assessment of TLR7 and TLR8 activity The ability of compounds to activate human TLR7 and/or TLR8 was assessed in a cellular reporter assay using HEK293 cells transiently transfected with a TLR7 or TLR8 expression vector and N FKB-IUC reporter construct.
Briefly, HEK293 cells were grown in culture medium (DMEM supplemented with 10% FCS and 2 mM Glutamine). For transfection of cells in 15 cm dishes, cells were detached with Trypsin-EDTA, transfected with a mix of CMV-TLR7 or TLR8 plasmid (1700 ng), N FKB-IUC plasmid (850 ng) and a transfection reagent and incubated for 48 h at 37°C in a humidified 5% CO2 atmosphere. Transfected cells were then washed in PBS, detached with Trypsin-EDTA and resuspended in medium to a density of 1 .25 x 105 cells/mL. Forty microliters of cells were then dispensed into each well in 384-well plates, where 200 nL of compound in 100% DMSO was already present. Following 6 hours incubation at 37°C, 5% CO2, the luciferase activity was determined by adding 15 μί of Steady Lite Plus substrate (Perkin Elmer) to each well and readout performed on a ViewLux ultraHTS microplate imager (Perkin Elmer). Dose response curves were generated from measurements performed in quadruplicates. Lowest effective concentrations (LEC) values, defined as the concentration that induces an effect which is at least two fold above the standard deviation of the assay, were determined for each compound. Compound toxicity was determined in parallel using a similar dilution series of compound with 40 μί per well of cells transfected with the CMV-TLR7 construct alone (1 .25 x 105 cells/mL), in 384-well plates. Cell viability was measured after 6 hours incubation at 37°C, 5% CO2 by adding 15 μί of ATP lite (Perkin Elmer) per well and reading on a ViewLux ultraHTS microplate imager (Perkin Elmer). Data was reported as CC50.
In parallel, a similar dilution series of compound was used (200 nL of compound in 100% DMSO) with 40 μί per well of cells transfected with N FKB- IUC reporter construct alone (1 .25 x 105 cells/mL). Six hours after incubation at 37°C, 5% CO2, the luciferase activity was determined by adding 15 μΙ of Steady Lite Plus substrate (Perkin Elmer) to each well and readout performed on a ViewLux ultraHTS microplate imager (Perkin Elmer). Counterscreen data is reported as LEC.
Activation of ISRE promoter elements
The potential of compounds to induce IFN-I was also evaluated by measuring the activation of interferon-stimulated responsive elements (ISRE) by conditioned media from PBMC. The ISRE element of sequence GAAACTGAAACT is highly responsive to the STAT1 -STAT2-IRF9 transcription factor, activated upon binding of IFN-I to their receptor IFNAR (Clontech, PT3372-5W). The plasmid pISRE-Luc from Clontech (ref. 631913) contains 5 copies of this ISRE element, followed by the firefly luciferase ORF. A HEK293 cell line stably transfected with pISRE-Luc (HEK-ISREluc) was established to profile the conditioned PBMC cell culture media.
Briefly, PBMCs were prepared from buffy coats of at least two donors using a standard Ficoll centrifugation protocol. Isolated PBMCs were resuspended in RPMI medium supplemented with 10% human AB serum and 2 x 105 cells/well were dispensed into 384-well plates containing compounds (70 μΙ_ total volume). After overnight incubation, 10 μΙ_ of supernatant was transferred to 384-well plates containing 5 x 103 HEK-ISREluc cells/well in 30 μΙ_ (plated the day before). Following 24 hours of incubation, activation of the ISRE elements was measured by assaying luciferase activity using 40 L/well Steady Lite Plus substrate (Perkin Elmer) and measured with ViewLux ultraHTS microplate imager (Perkin Elmer). The stimulating activity of each compound on the HEK- ISREluc cells was reported as LEC value, defined as the compound concentration applied to the PBMCs resulting in a luciferase activity at least two fold above the standard deviation of the assay. The LEC in turn indicates the degree of ISRE activation on transfer of a defined amount of PBMC culture medium. Recombinant interferon a-2a (Roferon-A) was used as a standard control compound.
TABLE VI: BIOLOGICAL ACTIVITY.
# Human TLR 7 Human TLR 8 HEK-ISRE luc
(LEC) μΜ (LEC) μΜ (LEC) μΜ
1 0.72 >25 0.61
2 0.94 >25 0.49
3 0.76 >25 0.47
4 0.92 19.8 0.59
5 0.53 14.7 0.1 1
6 3.75 >25 0.64
7 0.82 16.4 0.38
8 4.94 NA 2.1 1 # Human TLR 7 Human TLR 8 HEK-ISRE luc
(LEC) μΜ (LEC) μΜ (LEC) μΜ
9 5.21 >25 1.68
10 0.42 12.3 0.1 1
1 1 0.45 3.09 0.082
12 0.047 1.94 0.036
13 0.46 5.22 0.12
14 0.65 >25 0.13
15 0.61 >25 0.56
16 2.44 9.14 0.55
17 0.83 5.51 0.16
18 8.25 24.3 7.83
19 0.1 1 1.74 0.051
20 1.46 >25 0.62
21 6.1 8.85 0.54
22 14.7 >25 2.20
23 6.67 >25 1.62
24 14.3 1 1.0 1.75
25 1.95 6.62 0.49
26 2.14 >25 7.33
27 8.24 >25 5.04
28 2.24 >25 1.57
29 0.082 8.15 NA
30 0.63 9.0 0.14
31 0.74 >25 0.46
32 NA NA NA
NA = not available. All compounds showed no toxicity up to the highest tested concentration. All compounds showed no activity (LEC >25 μΜ) in the HEK 293 NF-kB counterscreen assay described above.

Claims

Claims
1 . A compound of formula (I)
Figure imgf000030_0001
or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof, wherein
Ri is any of the following structures
Figure imgf000030_0002
Figure imgf000030_0003
Figure imgf000030_0004
R2 is hydrogen, -O-(Ci-3)-alkyl, halogen, (Ci-3)-alkyl, -O-(Ci-3)-alkyl-O-(Ci-3)- alkyl or CH2OH;
R3 is hydrogen, -O-(Ci-3)-alkyl, halogen, (Ci-3)-alkyl or -C(=O)-R7 wherein R7 is -O-(Ci-3)-alkyl, NH2, NH(CH3) , N(CH3)2, N(CH3)(Ci-3)-alkyl, N((Ci-3)-alkyl)2 or pyrolidine;
R4 is hydrogen or fluorine;
Rs is (Ci-3)-alkyl, (Ci-3)-fluoro-alkyl, or CH2OH;
R6 is NH2, NH(CH3) or N(CH3)2, (hetero)-anilines optionally substituted with one or more of R3, R9, R10 R11 or Ri2 or (hetero)-benzylamines optionally substituted with one or more of R3, R9, R10 R11 or Ri2,
R8, R9, R10, R11 and Ri2 which are the same or different, are each independently selected from hydrogen, (Ci-3)-alkyl, -O-(Ci-3)-alkyl or halogen, and
Ri3 is hydrogen, (Ci-3)-alkyl or (Ci-3)-fluoro-alkyl.
2. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms , solvate or polymorph thereof according to claim 1 together with one or more pharmaceutically acceptable excipients, diluents or carriers.
3. A compound of formula (I) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms, solvate or polymorph thereof according to claim 1 or a pharmaceutical composition according to claim 2 for use as a medicament.
4. A compound of formula (I) or a pharmaceutically acceptable salt, tautomer(s), stereo-isomeric forms , solvate or polymorph thereof according to claim 1 , or a pharmaceutical composition according to claim 2 for use in the treatment of a disorder in which the modulation of TLR7 and /or TLR8 is involved.
5. A substituted 2-amino-4-hydrox uinazoline having the following formula
Figure imgf000031_0001
PCT/EP2013/073901 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections WO2014076221A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
JP2015542270A JP6297055B2 (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
EA201590931A EA035431B1 (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives as tlr7 and/or tlr8 modulators for the treatment of viral infections
CN201380059827.3A CN105051018B (en) 2012-11-16 2013-11-15 For treating the 2- amino-quinazolines derivative of the heterocycle of viral infection being substituted
CA2886635A CA2886635C (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
US14/443,305 US9663474B2 (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
UAA201505893A UA118341C2 (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
BR112015011036-3A BR112015011036B1 (en) 2012-11-16 2013-11-15 Heterocyclic Substituted 2-Amino-quinazoline Derivatives, Pharmaceutical Composition
DK13789821.9T DK2925729T3 (en) 2012-11-16 2013-11-15 HETEROCYCLIC SUBSTITUTED 2-AMINOQUINAZOLINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
MX2015006197A MX361585B (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections.
KR1020157010310A KR102253773B1 (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
AU2013346793A AU2013346793B2 (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
EP13789821.9A EP2925729B1 (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
SG11201503042QA SG11201503042QA (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
NZ70622613A NZ706226A (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PL13789821T PL2925729T3 (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
ES13789821.9T ES2655843T3 (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-aminoquinazoline derivatives for the treatment of viral infections
IL237864A IL237864A (en) 2012-11-16 2015-03-22 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PH12015500983A PH12015500983A1 (en) 2012-11-16 2015-05-04 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
US15/591,473 US10253003B2 (en) 2012-11-16 2017-05-10 Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
US16/377,752 US10723707B2 (en) 2012-11-16 2019-04-08 Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12192970.7 2012-11-16
EP12192970 2012-11-16

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/443,305 A-371-Of-International US9663474B2 (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
US15/591,473 Continuation US10253003B2 (en) 2012-11-16 2017-05-10 Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections

Publications (1)

Publication Number Publication Date
WO2014076221A1 true WO2014076221A1 (en) 2014-05-22

Family

ID=47189782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/073901 WO2014076221A1 (en) 2012-11-16 2013-11-15 Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections

Country Status (21)

Country Link
US (3) US9663474B2 (en)
EP (1) EP2925729B1 (en)
JP (1) JP6297055B2 (en)
KR (1) KR102253773B1 (en)
CN (1) CN105051018B (en)
AU (1) AU2013346793B2 (en)
BR (1) BR112015011036B1 (en)
CA (1) CA2886635C (en)
CL (1) CL2015001265A1 (en)
DK (1) DK2925729T3 (en)
EA (1) EA035431B1 (en)
ES (1) ES2655843T3 (en)
IL (1) IL237864A (en)
MX (1) MX361585B (en)
MY (1) MY171115A (en)
NZ (2) NZ706226A (en)
PH (1) PH12015500983A1 (en)
PL (1) PL2925729T3 (en)
SG (1) SG11201503042QA (en)
UA (1) UA118341C2 (en)
WO (1) WO2014076221A1 (en)

Cited By (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141092A1 (en) 2015-03-04 2016-09-09 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
WO2017035230A1 (en) 2015-08-26 2017-03-02 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
WO2017106346A2 (en) 2015-12-15 2017-06-22 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
WO2017205115A1 (en) 2016-05-27 2017-11-30 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
WO2017205078A1 (en) 2016-05-27 2017-11-30 Gilead Sciences, Inc. Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
WO2018039531A1 (en) 2016-08-26 2018-03-01 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
WO2018045144A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018144605A1 (en) 2017-02-02 2018-08-09 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
WO2018144390A1 (en) 2017-01-31 2018-08-09 Gilead Sciences, Inc. Crystalline forms of tenofovir alafenamide
WO2018181420A1 (en) 2017-03-29 2018-10-04 大日本住友製薬株式会社 Vaccine adjuvant formulation
WO2018195321A1 (en) 2017-04-20 2018-10-25 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019040102A1 (en) 2017-08-22 2019-02-28 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. Conjugates and methods of use thereof for selective delivery of immune-modulatory agents
WO2019118884A1 (en) 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019166532A1 (en) 2018-03-01 2019-09-06 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2020010223A1 (en) 2018-07-06 2020-01-09 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2020010107A1 (en) 2018-07-03 2020-01-09 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
WO2020010200A1 (en) 2018-07-06 2020-01-09 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2020014643A1 (en) 2018-07-13 2020-01-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020022272A1 (en) 2018-07-23 2020-01-30 公益財団法人ヒューマンサイエンス振興財団 Composition containing influenza vaccine
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020056008A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Compositions for the treatment of disease with immune stimulatory conjugates
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CN111051296A (en) * 2017-08-17 2020-04-21 吉利德科学公司 Solid forms of HIV capsid inhibitors
CN111051297A (en) * 2017-08-17 2020-04-21 吉利德科学公司 Choline salt forms of HIV capsid inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
WO2020162705A1 (en) 2019-02-08 2020-08-13 성균관대학교산학협력단 Toll-like receptor 7 or 8 agonist-cholesterol complex, and use of same
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020236753A1 (en) 2019-05-21 2020-11-26 Gilead Sciences, Inc. Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2020255039A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
WO2020257407A1 (en) 2019-06-19 2020-12-24 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
WO2021011544A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
WO2021076908A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021087064A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
WO2021096860A1 (en) 2019-11-12 2021-05-20 Gilead Sciences, Inc. Mcl1 inhibitors
CN112839929A (en) * 2018-10-19 2021-05-25 正大天晴药业集团股份有限公司 TLR8 agonists
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021130638A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
WO2021177679A1 (en) 2020-03-02 2021-09-10 성균관대학교산학협력단 Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021222522A1 (en) 2020-05-01 2021-11-04 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2021262990A1 (en) 2020-06-25 2021-12-30 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2022006327A1 (en) 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Anti-asgr1 antibody conjugates and uses thereof
WO2022031057A1 (en) 2020-08-04 2022-02-10 성균관대학교산학협력단 Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
WO2022031021A1 (en) 2020-08-04 2022-02-10 성균관대학교산학협력단 Mrna vaccine comprising adjuvant capable of kinetic control
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2022031011A1 (en) 2020-08-04 2022-02-10 성균관대학교산학협력단 Kinetically acting adjuvant ensemble
US11267801B2 (en) 2018-02-15 2022-03-08 Gilead Sciences, Inc. Therapeutic compounds
US11286257B2 (en) 2019-06-28 2022-03-29 Gilead Sciences, Inc. Processes for preparing toll-like receptor modulator compounds
WO2022087149A2 (en) 2020-10-22 2022-04-28 Gilead Sciences, Inc. Interleukin-2-fc fusion proteins and methods of use
WO2022103758A1 (en) 2020-11-11 2022-05-19 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO2022217022A1 (en) 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
WO2022221304A1 (en) 2021-04-14 2022-10-20 Gilead Sciences, Inc. CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER
WO2022226317A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023280227A2 (en) 2021-07-06 2023-01-12 Profoundbio Us Co. Linkers, drug linkers and conjugates thereof and methods of using the same
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023102239A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
RU2800877C2 (en) * 2018-09-19 2023-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Tlr8 agonist
WO2023147418A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. Parp7 inhibitors
US11760746B2 (en) 2018-02-16 2023-09-19 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023196875A1 (en) 2022-04-06 2023-10-12 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2023196784A1 (en) 2022-04-05 2023-10-12 Gilead Sciences, Inc. Combinations of antibody therapies for treating colorectal cancer
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US12054482B2 (en) 2018-09-19 2024-08-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TLR8 agonist

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62254B1 (en) 2011-04-08 2021-09-30 Janssen Sciences Ireland Unlimited Co Pyrimidine derivatives for the treatment of viral infections
SG11201401244TA (en) 2011-11-09 2014-09-26 Janssen R & D Ireland Purine derivatives for the treatment of viral infections
PL2872515T3 (en) 2012-07-13 2017-05-31 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
PT2906563T (en) 2012-10-10 2018-05-23 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
DK2925729T3 (en) 2012-11-16 2018-01-22 Janssen Sciences Ireland Uc HETEROCYCLIC SUBSTITUTED 2-AMINOQUINAZOLINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
KR102300861B1 (en) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 2-aminopyrimidine derivatives for the treatment of viral infections
SG11201508078XA (en) 2013-03-29 2015-11-27 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
CN105377833B (en) 2013-05-24 2018-11-06 爱尔兰詹森科学公司 Pyridione derivatives for treating virus infection and other disease
DK3030563T3 (en) 2013-06-27 2017-11-20 Janssen Sciences Ireland Uc PYRROLO- [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
ES2836881T3 (en) 2013-07-30 2021-06-28 Janssen Sciences Ireland Unlimited Co Derivatives of thieno [3,2-d] pyrimidines for the treatment of viral infections
KR20180099839A (en) * 2016-01-07 2018-09-05 얀센 사이언시즈 아일랜드 유씨 Functionalized pentanoic acid for use in influenza virus infections
JP7171444B2 (en) 2016-07-01 2022-11-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Dihydropyranopyrimidines for treating viral infections
ES2912945T3 (en) 2016-09-29 2022-05-30 Janssen Sciences Ireland Unlimited Co Pyrimidine prodrugs for the treatment of viral infections and other diseases
CN109867627B (en) * 2018-02-07 2021-05-07 南方医科大学 Substituted phenol beta-aminoalcohol derivative and its preparation method and use
CN115175906A (en) * 2020-03-18 2022-10-11 正大天晴药业集团股份有限公司 TLR8 agonist crystal form

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001448A1 (en) 1996-07-03 1998-01-15 Japan Energy Corporation Novel purine derivatives
WO1999028321A1 (en) 1997-11-28 1999-06-10 Sumitomo Pharmaceuticals Company, Limited Novel heterocyclic compounds
JP2000053653A (en) * 1998-08-10 2000-02-22 Sumitomo Pharmaceut Co Ltd Quinazoline derivative
WO2006117670A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
WO2008009078A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2009067081A1 (en) 2007-11-22 2009-05-28 Astrazeneca Ab Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis
WO2012156498A1 (en) * 2011-05-18 2012-11-22 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2610889B2 (en) 1987-09-03 1997-05-14 日本臓器製薬株式会社 New crosslinked adenine derivatives
WO1995034311A1 (en) * 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
AU735401B2 (en) 1996-08-28 2001-07-05 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
CA2267103C (en) 1996-10-04 2006-05-30 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof
AR012634A1 (en) 1997-05-02 2000-11-08 Sugen Inc QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
ATE245641T1 (en) 1998-02-17 2003-08-15 Tularik Inc ANTIVIRAL PYRIMIDINE DERIVATIVES
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP4315300B2 (en) 1998-08-10 2009-08-19 大日本住友製薬株式会社 Novel quinazoline derivatives
US6458798B1 (en) 1998-08-27 2002-10-01 Sumitomo Pharmaceuticals Company, Limited Bicyclic pyrimidine compounds and therapeutic use thereof
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
CA2323008C (en) 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
ATE402164T1 (en) * 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd NITROGEN CONTAINING COMPOUND HAVING A CONDENSED RING AND PYRAZOLYL GROUP AS A SUBSTITUENT AND MEDICAL COMPOSITION THEREOF
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
AU2002364211A1 (en) 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
NZ539064A (en) 2002-09-27 2007-09-28 Dainippon Sumitomo Pharma Co Novel adenine compound and use thereof
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
MXPA05013922A (en) 2003-06-20 2006-02-24 Coley Pharm Group Inc Small molecule toll-like receptor (tlr) antagonists.
OA13310A (en) 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.
TWI414525B (en) 2004-03-26 2013-11-11 Dainippon Sumitomo Pharma Co 9-substituted-8-oxoadenine compound
WO2005092892A1 (en) 2004-03-26 2005-10-06 Dainippon Sumitomo Pharma Co., Ltd. 8-oxoadenine compound
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
CN101035773B (en) 2004-08-10 2012-06-06 詹森药业有限公司 HIV inhibiting 1.2.4-triazin-6-one derivates
MX2007005408A (en) 2004-11-09 2007-05-16 Hoffmann La Roche Aminoquinazolines compounds.
US7498409B2 (en) 2005-03-24 2009-03-03 Schering Corporation Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists
AR054122A1 (en) 2005-05-12 2007-06-06 Tibotec Pharm Ltd PIRIDO [2,3-D] USEFUL PYRIMIDES AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION OF THE SAME
US7994360B2 (en) 2005-05-16 2011-08-09 Xtl Biopharmaceuticals Ltd. Benzofuran compounds
CA2619919C (en) 2005-09-01 2014-04-01 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
EP1939198A4 (en) 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co Novel adenine compound
US20070099941A1 (en) 2005-11-02 2007-05-03 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1970373A1 (en) 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
EP1987030B1 (en) 2006-02-17 2011-11-09 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
KR101507182B1 (en) 2006-12-07 2015-03-30 제넨테크, 인크. Phosphoinositide 3-kinase inhibitor compounds and methods of use
US8101595B2 (en) 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
DK2510946T3 (en) 2007-02-07 2015-11-02 Univ California Conjugates of synthetic fluorescent agonists and their applications
JP2008222557A (en) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk PYRROLO[3,2-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS EFFECTIVE COMPONENT
DK2132209T3 (en) 2007-03-19 2014-04-14 Astrazeneca Ab 9-SUBSTITUTED 8-OXO ADENINE COMPOUNDS AS MODULATORS OF TLR7 (TOLL-LIKE RECEPTOR 7)
PE20081887A1 (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co NEW ADENINE COMPOUND
JPWO2008114819A1 (en) 2007-03-20 2010-07-08 大日本住友製薬株式会社 New adenine compounds
JP5268120B2 (en) 2007-05-22 2013-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzimidazolone chymase inhibitor
US7968544B2 (en) 2007-06-29 2011-06-28 Gilead Sciences, Inc. Modulators of toll-like receptor 7
CN101842098A (en) 2007-08-10 2010-09-22 基因实验室技术有限公司 The nitrogenous bicyclo-chemical entities that is used for the treatment of viral infection
MX2010002336A (en) 2007-08-28 2010-03-25 Irm Llc Compounds and compositions as kinase inhibitors.
WO2009030998A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Pyrimidine compounds as toll-like receptor (tlr) agonists
ES2389994T3 (en) 2007-12-24 2012-11-05 Janssen R&D Ireland Macrocyclic Indoles as hepatitis C virus inhibitors
JP2011511073A (en) 2008-02-07 2011-04-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Treatment of bladder disease with TLR7 activator
CN102014911A (en) 2008-04-28 2011-04-13 默沙东公司 HCV NS3 protease inhibitors
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
UY31982A (en) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED
CA2760766A1 (en) 2009-05-21 2010-11-25 Nicholas James Bennett Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (en) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 Compounds for the reduction of β-amyloid production
WO2011049988A2 (en) 2009-10-20 2011-04-28 Eiger Biopharmaceuticals, Inc. Indazoles to treat flaviviridae virus infection
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
KR101094446B1 (en) 2009-11-19 2011-12-15 한국과학기술연구원 2,4,7-Substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors
JP2013032290A (en) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd Novel fused pyrimidine derivative
DE102010040233A1 (en) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclic aza heterocycles and their use
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012079079A1 (en) * 2010-12-10 2012-06-14 President And Fellows Of Harvard College Production of induced pluripotent stem cells
RS62254B1 (en) 2011-04-08 2021-09-30 Janssen Sciences Ireland Unlimited Co Pyrimidine derivatives for the treatment of viral infections
SG11201401244TA (en) 2011-11-09 2014-09-26 Janssen R & D Ireland Purine derivatives for the treatment of viral infections
ES2716811T3 (en) 2012-02-08 2019-06-17 Janssen Sciences Ireland Unlimited Co Piperidinopyrimidine derivatives for the treatment of viral infections
RS61664B1 (en) 2012-04-24 2021-04-29 Vertex Pharma Dna-pk inhibitors
PL2872515T3 (en) 2012-07-13 2017-05-31 Janssen Sciences Ireland Uc Macrocyclic purines for the treatment of viral infections
KR102280589B1 (en) 2012-08-10 2021-07-22 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
EP2712866A1 (en) 2012-10-01 2014-04-02 Centre National de la Recherche Scientifique (CNRS) 1,2,4-triazine derivatives for the treatment of viral infections
DK2903967T6 (en) 2012-10-05 2020-07-13 Janssen Sciences Ireland Unlimited Co ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS AND OTHER DISEASES
PT2906563T (en) 2012-10-10 2018-05-23 Janssen Sciences Ireland Uc Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
DK2925729T3 (en) 2012-11-16 2018-01-22 Janssen Sciences Ireland Uc HETEROCYCLIC SUBSTITUTED 2-AMINOQUINAZOLINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
KR102300861B1 (en) 2013-02-21 2021-09-10 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 2-aminopyrimidine derivatives for the treatment of viral infections
SG11201508078XA (en) 2013-03-29 2015-11-27 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
ES2836881T3 (en) 2013-07-30 2021-06-28 Janssen Sciences Ireland Unlimited Co Derivatives of thieno [3,2-d] pyrimidines for the treatment of viral infections
US9701661B2 (en) 2014-07-11 2017-07-11 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998001448A1 (en) 1996-07-03 1998-01-15 Japan Energy Corporation Novel purine derivatives
WO1999028321A1 (en) 1997-11-28 1999-06-10 Sumitomo Pharmaceuticals Company, Limited Novel heterocyclic compounds
JP2000053653A (en) * 1998-08-10 2000-02-22 Sumitomo Pharmaceut Co Ltd Quinazoline derivative
WO2006117670A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
WO2008009078A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2009067081A1 (en) 2007-11-22 2009-05-28 Astrazeneca Ab Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis
WO2012156498A1 (en) * 2011-05-18 2012-11-22 Janssen R&D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKIRA, S.; TAKEDA, K.; KAISHO, T., ANNUAL REV. IMMUNOLOGY, vol. 21, 2003, pages 335 - 376
HOFFMANN, J.A., NATURE, vol. 426, 2003, pages 33 - 38
ULEVITCH, R. J., NATURE REVIEWS: IMMUNOLOGY, vol. 4, 2004, pages 512 - 520

Cited By (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112174960A (en) * 2015-03-04 2021-01-05 吉利德科学公司 Toll-like receptor modulating 4, 6-diamino-pyrido [3,2-D ] pyrimidine compounds
JP2017509667A (en) * 2015-03-04 2017-04-06 ギリアード サイエンシーズ， インコーポレイテッド Toll-like receptor modulating 4,6-diamino-pyrido [3,2-d] pyrimidine compounds
KR102335970B1 (en) 2015-03-04 2021-12-07 길리애드 사이언시즈, 인코포레이티드 Toll like receptor modulator compounds
CN112174960B (en) * 2015-03-04 2023-10-10 吉利德科学公司 Toll-like receptor modulating 4, 6-diamino-pyrido [3,2-D ] pyrimidine compounds
US9670205B2 (en) 2015-03-04 2017-06-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2016141092A1 (en) 2015-03-04 2016-09-09 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
KR101756050B1 (en) 2015-03-04 2017-07-07 길리애드 사이언시즈, 인코포레이티드 Toll like receptor modulator compounds
EP3722297A1 (en) 2015-03-04 2020-10-14 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
JP2017203033A (en) * 2015-03-04 2017-11-16 ギリアード サイエンシーズ， インコーポレイテッド TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-d]PYRIMIDINE COMPOUNDS
KR20210151993A (en) * 2015-03-04 2021-12-14 길리애드 사이언시즈, 인코포레이티드 Toll like receptor modulator compounds
KR102394917B1 (en) 2015-03-04 2022-05-09 길리애드 사이언시즈, 인코포레이티드 Toll like receptor modulator compounds
KR20170114273A (en) * 2015-03-04 2017-10-13 길리애드 사이언시즈, 인코포레이티드 Toll like receptor modulator compounds
JP7268064B2 (en) 2015-03-04 2023-05-02 ギリアード サイエンシーズ， インコーポレイテッド Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
EA035093B1 (en) * 2015-03-04 2020-04-27 Джилид Сайэнс, Инк. TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-d]PYRIMIDINE COMPOUNDS
EP3321265A1 (en) 2015-03-04 2018-05-16 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine compounds and their utilisation as modulators of toll-like receptors
JP2021046456A (en) * 2015-03-04 2021-03-25 ギリアード サイエンシーズ， インコーポレイテッド TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-d]PYRIMIDINE COMPOUND
US10285990B2 (en) 2015-03-04 2019-05-14 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2017035230A1 (en) 2015-08-26 2017-03-02 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
EP3992206A1 (en) 2015-12-15 2022-05-04 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
WO2017106346A2 (en) 2015-12-15 2017-06-22 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
WO2017205115A1 (en) 2016-05-27 2017-11-30 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
WO2017205078A1 (en) 2016-05-27 2017-11-30 Gilead Sciences, Inc. Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
EP3922634A1 (en) 2016-08-26 2021-12-15 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
WO2018039531A1 (en) 2016-08-26 2018-03-01 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
WO2018045144A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
US11827609B2 (en) 2016-09-02 2023-11-28 Gilead Sciences, Inc. Toll like receptor modulator compounds
US11124487B2 (en) 2016-09-02 2021-09-21 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
US11274285B2 (en) 2016-10-14 2022-03-15 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome
WO2018144390A1 (en) 2017-01-31 2018-08-09 Gilead Sciences, Inc. Crystalline forms of tenofovir alafenamide
EP4424374A2 (en) 2017-01-31 2024-09-04 Gilead Sciences, Inc. Crystalline forms of tenofovir alafenamide
US10442804B2 (en) 2017-02-02 2019-10-15 Gilead Sciences, Inc. Compounds for the treatment of hepatitis B virus infection
WO2018144605A1 (en) 2017-02-02 2018-08-09 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
WO2018181420A1 (en) 2017-03-29 2018-10-04 大日本住友製薬株式会社 Vaccine adjuvant formulation
WO2018195321A1 (en) 2017-04-20 2018-10-25 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP4026835A2 (en) 2017-04-20 2022-07-13 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN111051297A (en) * 2017-08-17 2020-04-21 吉利德科学公司 Choline salt forms of HIV capsid inhibitors
US11267799B2 (en) 2017-08-17 2022-03-08 Gilead Sciences, Inc. Solid forms of an HIV capsid inhibitor
CN111051296A (en) * 2017-08-17 2020-04-21 吉利德科学公司 Solid forms of HIV capsid inhibitors
US11266638B2 (en) 2017-08-17 2022-03-08 Gilead Sciences, Inc. Choline salt forms of an HIV capsid inhibitor
US11833143B2 (en) 2017-08-17 2023-12-05 Gilead Sciences, Inc. Choline salt forms of an HIV capsid inhibitor
US11845739B2 (en) 2017-08-17 2023-12-19 Gilead Sciences, Inc. Solid forms of an HIV capsid inhibitor
WO2019040102A1 (en) 2017-08-22 2019-02-28 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. Conjugates and methods of use thereof for selective delivery of immune-modulatory agents
WO2019118884A1 (en) 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP4227302A1 (en) 2018-02-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11267801B2 (en) 2018-02-15 2022-03-08 Gilead Sciences, Inc. Therapeutic compounds
US11753399B2 (en) 2018-02-15 2023-09-12 Gilead Sciences, Inc. Therapeutic compounds
US11760746B2 (en) 2018-02-16 2023-09-19 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
EP4059924A1 (en) 2018-03-01 2022-09-21 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof
WO2019166532A1 (en) 2018-03-01 2019-09-06 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof
US11597704B2 (en) 2018-03-01 2023-03-07 Janssen Sciences Ireland Unlimited Company 2,4-diaminoquinazoline derivatives and medical uses thereof
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
US11292812B2 (en) 2018-04-06 2022-04-05 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotides
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
US11149052B2 (en) 2018-04-06 2021-10-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US11788077B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2020010107A1 (en) 2018-07-03 2020-01-09 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
EP4257600A2 (en) 2018-07-03 2023-10-11 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
US11098027B2 (en) 2018-07-06 2021-08-24 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2020010223A1 (en) 2018-07-06 2020-01-09 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
US11186579B2 (en) 2018-07-06 2021-11-30 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2020010200A1 (en) 2018-07-06 2020-01-09 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
WO2020014643A1 (en) 2018-07-13 2020-01-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP4234030A2 (en) 2018-07-13 2023-08-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
WO2020022272A1 (en) 2018-07-23 2020-01-30 公益財団法人ヒューマンサイエンス振興財団 Composition containing influenza vaccine
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020056008A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Compositions for the treatment of disease with immune stimulatory conjugates
US12054482B2 (en) 2018-09-19 2024-08-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TLR8 agonist
RU2800877C2 (en) * 2018-09-19 2023-07-31 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Tlr8 agonist
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CN112839929B (en) * 2018-10-19 2023-07-14 正大天晴药业集团股份有限公司 TLR8 agonists
EP3875451A4 (en) * 2018-10-19 2022-07-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tlr8 agonist
US12071435B2 (en) 2018-10-19 2024-08-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TLR8 agonist
CN112839929A (en) * 2018-10-19 2021-05-25 正大天晴药业集团股份有限公司 TLR8 agonists
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP4371987A1 (en) 2018-10-31 2024-05-22 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020162705A1 (en) 2019-02-08 2020-08-13 성균관대학교산학협력단 Toll-like receptor 7 or 8 agonist-cholesterol complex, and use of same
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
US11583531B2 (en) 2019-04-17 2023-02-21 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11396509B2 (en) 2019-04-17 2022-07-26 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020236753A1 (en) 2019-05-21 2020-11-26 Gilead Sciences, Inc. Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020255039A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
WO2020255038A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2020257407A1 (en) 2019-06-19 2020-12-24 Silverback Therapeutics, Inc. Anti-mesothelin antibodies and immunoconjugates thereof
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
US11286257B2 (en) 2019-06-28 2022-03-29 Gilead Sciences, Inc. Processes for preparing toll-like receptor modulator compounds
WO2021011544A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021067644A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
WO2021076908A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
EP4349413A2 (en) 2019-10-18 2024-04-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021087064A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
WO2021096860A1 (en) 2019-11-12 2021-05-20 Gilead Sciences, Inc. Mcl1 inhibitors
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021130638A1 (en) 2019-12-24 2021-07-01 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
WO2021163064A2 (en) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
WO2021177679A1 (en) 2020-03-02 2021-09-10 성균관대학교산학협력단 Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021222522A1 (en) 2020-05-01 2021-11-04 Gilead Sciences, Inc. Cd73 inhibiting 2,4-dioxopyrimidine compounds
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
US11680064B2 (en) 2020-06-25 2023-06-20 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
US12077537B2 (en) 2020-06-25 2024-09-03 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
WO2021262990A1 (en) 2020-06-25 2021-12-30 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
US11541126B1 (en) 2020-07-01 2023-01-03 Silverback Therapeutics, Inc. Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof
WO2022006327A1 (en) 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Anti-asgr1 antibody conjugates and uses thereof
WO2022031021A1 (en) 2020-08-04 2022-02-10 성균관대학교산학협력단 Mrna vaccine comprising adjuvant capable of kinetic control
WO2022031057A1 (en) 2020-08-04 2022-02-10 성균관대학교산학협력단 Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
WO2022031011A1 (en) 2020-08-04 2022-02-10 성균관대학교산학협력단 Kinetically acting adjuvant ensemble
WO2022031894A1 (en) 2020-08-07 2022-02-10 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2022087149A2 (en) 2020-10-22 2022-04-28 Gilead Sciences, Inc. Interleukin-2-fc fusion proteins and methods of use
WO2022103758A1 (en) 2020-11-11 2022-05-19 Gilead Sciences, Inc. METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
WO2022217022A1 (en) 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
WO2022221304A1 (en) 2021-04-14 2022-10-20 Gilead Sciences, Inc. CO-INHIBITION OF CD47/SIRPα BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER
WO2022226317A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023280227A2 (en) 2021-07-06 2023-01-12 Profoundbio Us Co. Linkers, drug linkers and conjugates thereof and methods of using the same
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2023102239A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
US12084467B2 (en) 2021-12-03 2024-09-10 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
WO2023107956A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023147418A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. Parp7 inhibitors
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183817A1 (en) 2022-03-24 2023-09-28 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023196784A1 (en) 2022-04-05 2023-10-12 Gilead Sciences, Inc. Combinations of antibody therapies for treating colorectal cancer
EP4310087A1 (en) 2022-04-06 2024-01-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2023196875A1 (en) 2022-04-06 2023-10-12 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Also Published As

Publication number Publication date
KR20150083842A (en) 2015-07-20
PH12015500983B1 (en) 2015-08-03
AU2013346793A1 (en) 2015-04-09
NZ748345A (en) 2020-04-24
CL2015001265A1 (en) 2015-08-28
US20150284339A1 (en) 2015-10-08
US20190330160A1 (en) 2019-10-31
JP2015537020A (en) 2015-12-24
PL2925729T3 (en) 2018-04-30
US20170349557A1 (en) 2017-12-07
US9663474B2 (en) 2017-05-30
KR102253773B1 (en) 2021-05-20
IL237864A (en) 2017-08-31
JP6297055B2 (en) 2018-03-20
EA201590931A1 (en) 2016-01-29
EA035431B1 (en) 2020-06-15
MX2015006197A (en) 2015-08-10
BR112015011036A2 (en) 2017-07-11
US10253003B2 (en) 2019-04-09
CN105051018A (en) 2015-11-11
NZ706226A (en) 2019-09-27
CA2886635A1 (en) 2014-05-22
BR112015011036B1 (en) 2022-02-01
AU2013346793B2 (en) 2018-03-08
MY171115A (en) 2019-09-26
UA118341C2 (en) 2019-01-10
MX361585B (en) 2018-12-11
SG11201503042QA (en) 2015-06-29
EP2925729A1 (en) 2015-10-07
CN105051018B (en) 2019-09-20
ES2655843T3 (en) 2018-02-21
US10723707B2 (en) 2020-07-28
EP2925729B1 (en) 2017-10-18
CA2886635C (en) 2021-01-05
DK2925729T3 (en) 2018-01-22
PH12015500983A1 (en) 2015-08-03

Similar Documents

Publication Publication Date Title
US10723707B2 (en) Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections
AU2018256591B2 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
US9284304B2 (en) Substituted pyrimidines as toll-like receptor modulators
DK2812331T3 (en) PIPERIDINOPYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS
CA3027471A1 (en) Dihydropyranopyrimidines for the treatment of viral infections
AU2018274911A1 (en) Pyrrolo[3,2-c]Pyrimidine derivatives for the treatment of viral infections and other diseases
WO2014128189A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
WO2014053516A1 (en) 1,2,4-triazine derivatives for the treatment of viral infections.
NZ709769B2 (en) 2-aminopyrimidine derivatives for the treatment of viral infections

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201380059827.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13789821

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 237864

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2886635

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013346793

Country of ref document: AU

Date of ref document: 20131115

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20157010310

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015542270

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12015500983

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: IDP00201502868

Country of ref document: ID

WWE Wipo information: entry into national phase

Ref document number: 14443305

Country of ref document: US

Ref document number: MX/A/2015/006197

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015011036

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2013789821

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013789821

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201590931

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 112015011036

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150514